Elsevier

Neuroscience Letters

Volume 297, Issue 2, 12 January 2001, Pages 97-100
Neuroscience Letters

Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide

https://doi.org/10.1016/S0304-3940(00)01675-XGet rights and content

Abstract

Neprilysin is an enzyme capable of degrading β-amyloid protein. We measured neprilysin mRNA and protein levels in brain and peripheral organs of Alzheimer disease (AD) and control cases. Neprilysin mRNA levels were lowest in the hippocampus and temporal gyrus, which are vulnerable to senile plaque development. They were highest in the caudate and peripheral organs which are resistant to senile plaque development. Levels in AD were significantly lower than controls in the hippocampus and midtemporal gyrus but not in other brain areas or peripheral organs. We also measured levels of the mRNA for the neuronal marker microtubule-associated protein-2. They were remarkably constant in all brain areas and were not lowered in AD, indicating that the neprilysin mRNA reduction in the hippocampus and temporal gyrus was not correlated with simple neuronal loss. Relative levels of neprilysin protein generally paralleled those of the mRNA. These results suggest that deficient degradation of β-amyloid protein caused by low levels of neprilysin may contribute to AD pathogenesis.

Section snippets

Acknowledgements

This research was supported by a grants from the Jack Brown and Family A.D. Research Fund, as well as donations from The Friends of UBC and individual British Columbians.

Cited by (319)

  • Futuristic aspect of nanocarriers on targeted delivery for dementia

    2023, Nanomedicine-Based Approaches for the Treatment of Dementia
  • Hypothesis: Intravenous administration of mesenchymal stem cells is effective in the treatment of Alzheimer's disease

    2021, Medical Hypotheses
    Citation Excerpt :

    Neprilysin regulates amyloid-β peptide levels [9]. Neprilysin activity is reduced in the brains of Alzheimer's patients, especially in areas where amyloid is deposited [10]. Mesenchymal stem cells administered intravenously through a drip can be used to regenerate the brain.

View all citing articles on Scopus
View full text